Prevalence of hepatitis C in people who inject drugs in the cities of Rawalpindi and Islamabad, Pakistan

  • Authors:
    • Yasir Waheed
    • Muzammil Hasan Najmi
    • Hafsa Aziz
    • Hasnain Waheed
    • Muhammad Imran
    • Sher Zaman Safi
  • View Affiliations

  • Published online on: August 1, 2017     https://doi.org/10.3892/br.2017.959
  • Pages: 263-266
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pakistan has the second highest burden of hepatitis C (HCV) in the world. The major route of HCV transmission is contaminated blood or needle sharing. Seventy percent of people who inject drugs (PWIDs) shared needles at some time in their addiction history. The aim of the present study was to estimate the prevalence of HCV in PWIDs in cities of Pakistan. We enrolled 100 PWIDs from the Rawalpindi and Islamabad cities of Pakistan. Blood samples were taken in collection tubes and were subjected to HCV screening by using three rapid HCV screening kits including one step anti‑HCV test, onsite HCV Ab rapid test and advance quality rapid anti-HCV test. All 100 blood samples were also subjected to HCV detection by using Elecsys anti-HCV II performed on the Roche Cobas 601 platform based on the ECLIA principle. Seventy-two percent of PWIDs showed the presence of HCV antibodies using the Roche anti-HCV II ECLIA test. We also compared the performance of different rapid kits in comparison with the anti-HCV II by Roche. The sensitivity of CTK kit was 84.72%, which was almost equal to the sensitivity by the SD Bioline HCV and Advanced Quality Rapid HCV tests, which was 83.33%. All three kits showed 100% specificity and positive predictive values. The results showed that the three market competitors of HCV rapid test showed almost equal results. The prevalence of HCV is very high in PWIDs in the capital twin cities of Pakistan. There is dire need to initiate the administration of a hepatitis test and treatment program for both high-risk and the general HCV-positive population. This is the optimal way to achieve HCV control targets established by the United Nations Sustainable Development Goals and Global Health Sector Strategy by WHO.

References

1 

World Health Organization, . Global health sector strategies on viral hepatitis 2016–2021. simplehttp://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_32-en.pdf?ua=1Accessed. May 29–2016.

2 

GBD 2013 Mortality and Causes of Death Collaborators: Global, regional and national age-sex specific all cause and cause specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the global burden of diseases study 2013. Lancet. 385:117–171. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Waheed Y, Shafi T, Safi SZ and Qadri I: Hepatitis C virus in Pakistan: A systematic review of prevalence, genotypes and risk factors. World J Gastroenterol. 15:5647–5653. 2009. View Article : Google Scholar : PubMed/NCBI

4 

Waheed Y, Saeed U, Anjum S, Afzal MS and Ashraf M: Development of global consensus sequence and analysis of highly conserved domains of HCV NS5B protein. Hepat Mon. 12:e61422012.PubMed/NCBI

5 

Waheed Y: Transition from millennium development goals to sustainable development goals and hepatitis. Pathog Glob Health. 109:3532015. View Article : Google Scholar : PubMed/NCBI

6 

Waheed Y: Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan: Treatment response, side effects and future prospective. Asian Pac J Trop Med. 8:85–89. 2015. View Article : Google Scholar : PubMed/NCBI

7 

Waheed Y: Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection. World J Virol. 4:33–35. 2015. View Article : Google Scholar : PubMed/NCBI

8 

United Nations Office on Drugs and Crime: Drug use in Pakistan 2013. simplehttps://www.unodc.org/documents/pakistan/Survey_Report_Final_2013.pdfAccessed. May 11–2016.

9 

Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D and Degenhardt L: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet. 378:571–583. 2011. View Article : Google Scholar : PubMed/NCBI

10 

UNAIDS: How AIDS changed everything. MDG6: 15 years, 15 lessons of hope from the AIDS response. simplehttp://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdfAccessed. June 4–2016.

11 

Akhtar AM and Majeed S, Jamil M, Rehman A and Majeed S: Hepatitis-C virus infection among injecting drug users in Lahore, Pakistan: A cross sectional study. Pak J Med Sci. 32:373–378. 2016.PubMed/NCBI

12 

ur Rehman L, Ullah I, Ali I, Khan IA, Iqbal A, Khan S, Khan SH, Zaman KU, ullah Khan N and Swati ZA: Active hepatitis C infection and HCV genotypes prevalent among the IDUs of Khyber Pakhtunkhwa. Virol J. 8:3272011. View Article : Google Scholar : PubMed/NCBI

13 

Altaf A, Saleem N, Abbas S and Muzaffar R: High prevalence of HIV infection among injection drug users (IDUs) in Hyderabad and Sukkur, Pakistan. J Pak Med Assoc. 59:136–140. 2009.PubMed/NCBI

14 

Platt L, Vickerman P, Collumbien M, Hasan S, Lalji N, Mayhew S, Muzaffar R, Andreasen A and Hawkes S: Prevalence of HIV, HCV and sexually transmitted infections among injecting drug users in Rawalpindi and Abbottabad, Pakistan: Evidence for an emerging injection-related HIV epidemic. Sex Transm Infect. 85:(Suppl 2). ii17–ii22. 2009. View Article : Google Scholar : PubMed/NCBI

15 

Achakzai M, Kassi M and Kasi PM: Seroprevalences and co-infections of HIV, hepatitis C virus and hepatitis B virus in injecting drug users in Quetta, Pakistan. Trop Doct. 37:43–45. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Kuo I, ul-Hasan S, Galai N, Thomas DL, Zafar T, Ahmed MA and Strathdee SA: High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. Harm Reduct J. 3:262006. View Article : Google Scholar : PubMed/NCBI

17 

Mumtaz GR, Weiss HA and Abu-Raddad LJ: Hepatitis C virus and HIV infections among people who inject drugs in the Middle East and North Africa: A neglected public health burden? J Int AIDS Soc. 18:205822015. View Article : Google Scholar : PubMed/NCBI

18 

Ahmad S, Mehmood J, Awan AB, Zafar ST, Khoshnood K and Khan AA: Female spouses of injection drug users in Pakistan: A bridge population of the HIV epidemic? East Mediterr Health J. 17:271–276. 2011.PubMed/NCBI

Related Articles

Journal Cover

September 2017
Volume 7 Issue 3

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Waheed, Y., Najmi, M.H., Aziz, H., Waheed, H., Imran, M., & Safi, S.Z. (2017). Prevalence of hepatitis C in people who inject drugs in the cities of Rawalpindi and Islamabad, Pakistan. Biomedical Reports, 7, 263-266. https://doi.org/10.3892/br.2017.959
MLA
Waheed, Y., Najmi, M. H., Aziz, H., Waheed, H., Imran, M., Safi, S. Z."Prevalence of hepatitis C in people who inject drugs in the cities of Rawalpindi and Islamabad, Pakistan". Biomedical Reports 7.3 (2017): 263-266.
Chicago
Waheed, Y., Najmi, M. H., Aziz, H., Waheed, H., Imran, M., Safi, S. Z."Prevalence of hepatitis C in people who inject drugs in the cities of Rawalpindi and Islamabad, Pakistan". Biomedical Reports 7, no. 3 (2017): 263-266. https://doi.org/10.3892/br.2017.959